Brokerages Set OPKO Health, Inc. (NASDAQ:OPK) Target Price at $1.55

OPKO Health, Inc. (NASDAQ:OPK) has been given a consensus recommendation of “Hold” by the six analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $1.55.

OPK has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. Wall Street Zen cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Barrington Research lowered their price target on OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a research report on Monday, March 2nd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of OPK. Cubist Systematic Strategies LLC boosted its position in shares of OPKO Health by 2,369.9% during the first quarter. Cubist Systematic Strategies LLC now owns 119,223 shares of the biotechnology company’s stock worth $198,000 after buying an additional 114,396 shares during the period. AQR Capital Management LLC boosted its position in shares of OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after buying an additional 1,324,988 shares during the period. Millennium Management LLC boosted its position in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after buying an additional 1,798,385 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of OPKO Health by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock worth $6,642,000 after buying an additional 161,394 shares during the period. Finally, Caxton Associates LLP purchased a new position in shares of OPKO Health during the first quarter worth $130,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health Price Performance

OPK stock opened at $1.24 on Friday. The business has a fifty day moving average of $1.18 and a two-hundred day moving average of $1.30. The company has a quick ratio of 3.52, a current ratio of 3.97 and a debt-to-equity ratio of 0.26. The stock has a market cap of $941.25 million, a price-to-earnings ratio of -4.13 and a beta of 1.49. OPKO Health has a 52-week low of $1.10 and a 52-week high of $1.60.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03. The company had revenue of $148.50 million during the quarter, compared to analysts’ expectations of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The firm’s quarterly revenue was down 19.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.01 earnings per share. As a group, research analysts anticipate that OPKO Health will post -0.25 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.